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Abstract. Muscle contraction requires specialized membrane structures with precise geometry and relies on the concerted
interplay of electrical stimulation and Ca2+ release, known as excitation-contraction coupling (ECC). The membrane structure
hosting ECC is called triad in skeletal muscle and dyad in cardiac muscle, and structural or functional defects of triads and
dyads have been observed in a variety of myopathies and cardiomyopathies. Based on their function, the proteins localized
at the triad/dyad can be classified into three molecular pathways: the Ca2+ release complex (CRC), store-operated Ca2+
entry (SOCE), and membrane remodeling. All three are mechanistically linked, and consequently, aberrations in any of these
pathways cause similar disease entities. This review provides an overview of the clinical and genetic spectrum of triad and
dyad defects with a main focus of attention on the underlying pathomechanisms.
Keywords: Triad, dyad, myopathy, cardiomyopathy, excitation-contraction coupling, ECC, store-operated Ca2+ entry, SOCE,
calcium, membrane remodeling
INTRODUCTION
Muscle contraction relies on the conversion of an
electrical stimulus into mechanical work. In skeletal
muscle, the sequence of events begins with the exci-
tation of a motor neuron and the subsequent release
of the neurotransmitter acetylcholine (ACh) into the
neuromuscular junction. Binding of ACh to ACh
receptors in the motor endplate triggers Na+ influx,
generating a local depolarization of the membrane
[1]. In cardiac muscle, membrane depolarization is
∗Correspondence to: Johann Bo¨hm and Jocelyn Laporte,
IGBMC, 1 Rue Laurent Fries, 67404 Illkirch, France. Tel.: +33
3 88 65 34 12; E-mails: johann@igbmc.fr; jocelyn@igbmc.fr.
not initiated by nervous activity, but by sinoatrial node
(SAN) cells in the right atrium, spontaneously gen-
erating 60–100 action potentials per minute [2]. The
action potential then spreads along the skeletal and
cardiac muscle cells and deep into membrane invagi-
nations known as T (transverse)-tubules [3]. Together
with the terminal cisternae of the sarcoplasmic retic-
ulum (SR), T-tubules form a specialized complex
known as triad in skeletal muscle and dyad in cardiac
muscle, hosting the excitation-contraction machinery
(ECC, Fig. 1) [4]. In detail, ECC is driven by the mul-
tiprotein Ca2+ release complex (CRC), composed of
the voltage-gated L-type Ca2+ channel dihydropyri-
dine receptor (DHPR) on the T-tubule, and ryanodine
receptor (RyR), triadin, calsequestrin, and junctin,
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all residing in the SR. In skeletal muscle, membrane
depolarization at the T-tubules causes the conforma-
tional change of the 1 subunit of DHPR, encoded
by CACNA1S, enabling its physical interaction with
the Ca2+ channel RyR1 across the membrane gap
between the T-Tubule and the SR [5]. This is different
to cardiac muscle, where membrane depolarization
triggers influx of extracellular Ca2+ through the
cardiac 1 subunit of DHPR (CACNA1C), and the
increased local Ca2+ levels then activate RyR2 via
a mechanism known as Ca2+-induced Ca2+ release
(CICR) [6]. Skeletal muscle and cardiac ryanodine
receptors are homotetrameric Ca2+ channels, and the
amount of released Ca2+ is regulated by a quater-
nary complex with junctin, calsequestrin and triadin
[7]. Ca2+ release finally triggers shortening of the
contractile unit, the sarcomere, composed of myosin
and actin filaments and various structural and regu-
latory elements. The myosin head thereby binds to
actin and performs a power stroke under ATP hydrol-
ysis, resulting in a relative movement of the filaments
and the generation of force [8]. Muscle relaxation
occurs when Ca2+ is removed from the contractile
unit through the combined action of Ca2+ pumps
and Na+/Ca2+ exchangers [9]. Repeated contrac-
tions require the maintenance of high Ca2+ gradients
and the strict regulation of luminal and cytosolic
Ca2+ balance. Store-operated Ca2+ entry (SOCE)
is a major mechanism regulating Ca2+ homeosta-
sis, and essentially depends on the interaction of the
reticular Ca2+ sensor STIM1 and the plasma mem-
brane Ca2+ channel ORAI1. Upon Ca2+ depletion,
STIM1 undergoes a conformational change and acti-
vates ORAI1 to induce extracellular Ca2+ influx,
and Ca2+ store refill is then ensured by the reticular
SERCA Ca2+ pumps [10–14].
Disturbances of Ca2+ homeostasis can severely
impact on muscle physiology, and structural or func-
tional triad or dyad defects give rise to various
myopathies and cardiac disorders (summarized in
Table 1). This review aims to provide a gene-by-
gene overview of the mutations leading to defects
of the Ca2+ release complex (CRC), store-operated
Ca2+ entry (SOCE), or membrane remodeling. The
mutations thereby often affect paralogue genes with
tissue-specific expression in skeletal muscle and
heart, emphasizing the parallelism of myopathies and
cardiomyopathies. We mainly focus on myopathies,
and we draw an analogy between the pathome-
chanisms underlying skeletal muscle and heart
dysfunction.
CA2+ RELEASE COMPLEX (CRC)
DISORDERS
Mutations in CACNA1S and CACNA1C
The dihydropyridine receptor (DHPR) is com-
posed of the five equimolar 1, 2, , δ, and 
subunits [15]. The voltage sensor and pore-forming
subunit 1, encoded by CACNA1S in skeletal muscle
and by CACNA1C in heart, contains four transmem-
brane domains (I–IV), and the cytoplasmic loop
between domains II and III mediates the activa-
tion of the ryanodine receptor in skeletal muscle
[16, 17]. CACNA1S mutations have been associated
with different disorders such as malignant hyper-
thermia (MH, OMIM #601887) [18], hypokalemic
periodic paralysis (HOKPP, OMIM #170400) [19],
and recently also with a new congenital myopa-
thy entity [20], while CACNA1C mutations have
been reported in Brugada syndrome (BrS, OMIM
#611875) [21] and in Timothy syndrome (TS, OMIM
#601005) [22].
Malignant hyperthermia (MH) is triggered by
volatile anesthetics, and major symptoms are uncon-
trolled contractures, muscle rigidity, hyperthermia,
cardiac arrhythmia, hyperkalemia, and hyperme-
tabolism [23, 24]. MH is potentially fatal if not
rapidly treated with the muscle relaxant dantrolene.
CACNA1S mutations account for less than 10 % of
the MH cases, and to date only three different het-
erozygous missense mutations have been reported
[18, 25, 26]. It has been shown that these mutations
increase the sensitivity of RyR1 to activation, lead-
ing to elevated resting Ca2+ levels in the cytosol
[27, 28]. Muscle biopsies from MH patients were
largely unremarkable and showed only minor alter-
ations of the mitochondrial shape and also manifested
mitochondrial breakdown, both potentially result-
ing from aberrant Ca2+ homeostasis in the muscle
fibers [29]. Hypokalemic periodic paralysis is char-
acterized by episodic and recurrent muscle weakness
leading to paraparesis or tetraparesis lasting sev-
eral hours to several days. The paralytic attacks
are accompanied by hypokalemia, and treatment
with the potassium channel opener acetazolamide
has been shown to be beneficial [30]. A subset of
HOKPP patients develop adult-onset myopathy, and
the causative CACNA1S missense mutations affect
a highly conserved arginine residue in the 1 volt-
age sensor domain [31]. Functional studies in the
mouse model demonstrated that the loss of the pos-
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Fig. 1. Schematic representation of the skeletal muscle triad and the cardiac muscle dyad and illustration of the fundamental key pathways.
SOCE (store-operated Ca2+ entry) controls Ca2+ homeostasis through the combined activity of STIM1 and ORAI1, membrane remodeling
depends on myotubularin (MTM1), amphiphysin 2 (BIN1), dynamin 2 (DNM2), caveolin-3 (CAV3), and dysferlin (DYSF), and the CRC
(Ca2+ release complex) involves DHPR and the complex composed of ryanodine receptor (RyR), calsequestrin (CASQ), and triadin (TRDN),
while junctophilin ties the sarcoplasmic reticulum with the T-tubule. Proteins marked in gray have not yet been associated with skeletal
muscle or heart disorders.
itive charge impacts on the gating properties of the
channel by causing an anomalous voltage-dependent
inward current [32]. CACNA1S mutations were also
associated with an unusual congenital myopathy with
both dominant and recessive disease inheritance [20].
All patients had a comparable clinical presentation of
generalized muscle weakness at birth, and the muscle
biopsies exhibited cores, central nuclei, dilated triads,
as well as a particular alveolar aspect of the intermy-
ofibrillar network. DHPR stimulation resulted in
significantly reduced reticular Ca2+ release in patient
myotubes, suggesting an uncoupling of DHPR and
RyR1 [20].
CACNA1C mutations have been found in patients
with Brugada syndrome and Timothy syndrome. Bru-
gada syndrome is a rare arrhythmia condition that
can cause fast polymorphic ventricular tachycardia or
ventricular fibrillation preceding sudden death [21].
The ECG pattern typically shows a persistent ST seg-
ment elevation with a right bundle branch block [21].
Heterozygous CACNA1C missense mutations only
account for a subset of Brugada syndrome cases,
and it has been shown that these mutations lead
to decreased Ca2+ channel activity [21]. Timothy
syndrome is a multi-systemic disorder combining a
congenital heart disease - including patent ductus
arteriosus, patent foramen ovale, ventricular sep-
tal defects, and tetralogy of Fallot - with immune
deficiency, syndactyly, and cognitive abnormalities
[22]. ECG typically reveals prolongation of the QT
interval, leading to life-threatening arrhythmias. In
contrast to Brugada syndrome, the Timothy syn-
drome mutations involve a gain-of-function and
lead to sustained depolarizing L-type Ca2+ currents
resulting from reduced channel inactivation [22].
Mutations in RYR1 and RYR2
The sarcoplasmic reticulum in skeletal and cardiac
muscle is composed of structurally and functionally
distinct domains, the junctional and the longitudinal
SR. The junctional SR is primarily involved in Ca2+
release and hosts the ryanodine receptor (RyR). Each
polypeptide of this homotetrameric protein is com-
posed of more than 5000 amino acids forming six
transmembrane domains. The C-terminal end of the
RyR protein constitutes the Ca2+ channel, and the
N-terminal cytoplasmic protrusion spans the narrow
gap separating the junctional SR from the T-tubule
[33–37]. Heterozygous missense mutations in RYR1
which account for the majority of molecularly diag-
nosed MH cases, render the channel hypersensitive
to triggering agents, and lead to excessive Ca2+
release from the SR [38, 39]. Mutations in RYR1
have also been found to cause King-Denborough syn-
drome (OMIM #145600) [40], central core disease
(CCD, OMIM #117000) [41, 42], multi-minicore dis-
ease (MmD, OMIM #255320) [43], centronuclear
myopathy (CNM), congenital fiber type dispropor-
tion (CFTD), and the Samaritan myopathy [44],
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underlining the phenotypic variability arising from
mutations in RYR1. RYR2 mutations have been
described in the allelic diseases catecholaminergic
polymorphic ventricular tachycardia (CPVT, OMIM
#604772) [45] and arrhythmogenic right ventricular
dysplasia 2 (ARVD2, OMIM # 600996) [46].
King-Denborough syndrome is a congenital
myopathy associated with skeletal abnormalities,
dysmorphic features, and susceptibility to malignant
hyperthermia [47]. Muscle biopsies show a variety
of myopathic features including atrophy, internalized
nuclei, or cores [48]. It is not understood how the
identified RYR1 mutations cause King-Denborough
syndrome, but they reside in the same regions as MH
mutations, indicating that both disorders might share
a common pathomechanism [48].
Central core disease has been named after the
central areas with reduced oxidative activity and
a variable degree of sarcomeric disorganization
running along the longitudinal muscle fiber axis.
Clinically, CCD can be stable over long periods and
typically presents with childhood-onset hypotonia,
proximal muscle weakness, mild facial weakness,
joint hypermobility, and scoliosis [49]. CCD is
mainly caused by heterozygous missense mutations
affecting amino acids in the C-terminal pore-forming
domain of RyR1, and more severe cases with a
fetal akinesia syndrome involving arthrogryposis and
skeletal deformities have been described with reces-
sive disease inheritance [50]. A subset of RYR1
mutations were found to generate a leaky channel
leading to Ca2+ store depletion, others alter the
interaction with DHPR and thereby uncouple exci-
tation from contraction. In both cases, the amount
of released Ca2+ upon depolarization is reduced
[51–53].
Multi-minicore disease results from recessive
RYR1 mutations dispersed over the entire gene, and
is usually associated with an earlier disease onset and
more severe clinical features with additional extraoc-
ular muscle involvement compared to CCD [43].
Biopsies from MmD patients display multiple areas
of reduced mitochondrial activity and sarcomeric
organization, and these minicores only span a lim-
ited zone on the longitudinal axis of the muscle fiber.
Most MmD cases arise from missense mutations, but
nonsense and splice site mutations have also been
described. Patients with a clinicopathologic diagno-
sis of centronuclear myopathy (CNM) were found to
carry recessive RYR1 missense or truncating muta-
tions as well [54]. The affected individuals had an
antenatal disease onset and were severely hypotonic
at birth. Similarly to MmD, the patients had delayed
motor milestones and showed facial weakness with
extraocular muscle involvement. The muscle biop-
sies displayed cores as well as centralized nuclei,
demonstrating a phenotypic overlap of RYR1-related
MmD and CNM. Another muscle disorder associated
with recessive missense and truncating RYR1 muta-
tions is congenital fiber type disproportion (CFTD)
[55]. The clinical presentation of the CFTD patients
is comparable to RYR1-related MmD and CNM, and
the muscle biopsies showed significantly smaller type
I fibers as the main histological hallmark, whereas
cores and centralized nuclei were not observed. The
Samaritan myopathy is a unique form of multi-
minicore disease, as it is characterized by an “inverse”
course of disease: affected individuals present with
a severe muscle phenotype at birth, but hypotonia
and muscle weakness gradually improve and adults
are only mildly affected [56]. This disease is caused
by a single homozygous missense mutation in RYR1
[44] and has only been described in the Samaritans,
considering themselves as descendants of one of the
twelve tribes forming the ancient kingdom of Israel in
the 8th century BCE. In both multi-minicore disease
and Samaritan myopathy, the RyR1 protein level was
found to be strongly reduced in muscle extracts from
affected individuals [44, 57], and siRNA-mediated
downregulation of RYR1 in myotubes led to reduced
CACNA1S expression and a disruption of the spa-
tial organization of the EC coupling machinery, while
IP3R was upregulated [58]. These findings illustrate
that RyR1 deficiency alters the expression pattern of
genes involved in Ca2+ homeostasis, and indicate that
the upregulation of the alternative Ca2+ regulating
IP3R system might be a compensatory mechanism.
Catecholaminergic polymorphic ventricular tachy-
cardia is an arrhythmogenic disorder caused by
heterozygous RYR2 mutations in more than 50% of
the cases [45]. CPVT patients have a structurally nor-
mal heart and a normal resting ECG. Physical activity
or stress can induce an increase of monomorphic
and then polymorphic premature ventricular contrac-
tions (PVCs), followed by polymorphic ventricular
tachycardia and ventricular fibrillation, possibly
leading to syncope or sudden death [59]. It was
shown that the RYR2 mutations alter the sensitivity
of the channel, which tends to spontaneous Ca2+
release under conditions of reticular Ca2+ over-
load (SOICR, store-overload-induced Ca2+ release)
[60, 61]. The mutations thereby do not appear to
impact on ECC, as arrhythmias are not observed
in unstimulated conditions. Dantrolene was shown
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to rescue arrhythmogenic RyR2 defects in cellular
CPVT models, indicating a common pathomecha-
nism for CPVT and malignant hyperthermia [62,
63]. Another heart disease caused by dominant RYR2
mutations is arrhythmogenic right ventricular dys-
plasia 2 (ARVD2), characterized by fibrous fatty
replacements of the myocardium and in particular
in the subepicardial layer of the right ventricle [46].
Physical effort can induce polymorphic ventricular
tachycardia, representing a risk of sudden death. The
ARVD2 mutations were shown to alter the RyR2
response to caffeine, resulting in an abnormal Ca2+
release [64]. The missense mutations causing either
CPVT or ARVD2 are conjointly clustered in distinct
N-terminal, central, and C-terminal regions of RyR2.
Mutations in STAC3
STAC3 is a recently discovered component of the
excitation-contraction machinery, and mutations in
STAC3 have been associated with the debilitating
Native American myopathy (NAM, OMIM #255995)
[65]. This autosomal recessive disorder was first
reported in the Lumbee Indian tribe in North Carolina
and is characterized by neonatal muscle weakness
and arthrogryposis, dysmorphic facial features, and
susceptibility to malignant hyperthermia with high
mortality rate in childhood and adolescence [66].
Muscle biopsies from affected individuals revealed
a non-specific myopathic pattern [65]. STAC3 pos-
sesses a functional interaction site for both the
skeletal muscle and cardiac 1 subunit of DHPR,
and promotes the localization of DHPR at the triad
membrane [67, 68], demonstrating the importance
of STAC3 in the regulation of excitation-contraction
coupling. Indeed, the NAM STAC3 missense muta-
tion was shown to reduce ECC [67], and the same
observation was also made in myotubes from Stac3
knockout mice and morpholino-induced knockdown
of stack3 in zebrafish embryos [65, 67].
Mutations in JPH2
The junctophilins are components of the junc-
tional membrane complex (JMC), which physically
and functionally connects the T-tubule with the SR
to maintain the triad and dyad architecture [69].
The cardiac paralogue junctophilin 2 is encoded by
JPH2, and mutations in this gene have been asso-
ciated with hypertrophic cardiomyopathy (CMH17,
OMIM #613873), one of the most common causes
for sudden cardiac death in young athletes [70]. The
JPH2 mutations were found to cause junctophilin 2
mislocalization, impaired Ca2+ handling, and car-
diomyocyte hypertrophy in the cellular model. A
murine model manifested pacing-induced sponta-
neous Ca2+ sparks followed by atrial fibrillations,
indicating that junctophilin 2 also has a regulatory
role on RyR2 [71].
Mutations in the ryanodine receptor effectors
TRDN, CASQ1, and CASQ2
Triadin physically links the ryanodine recep-
tor with calsequestrin [7], and recessive TRDN
mutations cause catecholaminergic polymorphic ven-
tricular tachycardia (CPVT, OMIM #615441) [72],
a major cause of sudden death. All CPVT muta-
tions were found in exons present in both the skeletal
muscle and the cardiac isoform, and resulted in tri-
adin protein loss. Accordingly, a subset of TRDN
patients manifested an additional skeletal muscle
disorder [73], and ablation of triadin in murine
knockout models resulted in cardiac and skele-
tal muscle phenotypes [74, 75]. The hearts of the
mice displayed lower expression levels of RYR2,
CASQ2, and ASPH (junctin), abnormal contact sites
between the T-tubules and the SR, as well as retic-
ular Ca2+ overload resulting in spontaneous Ca2+
release (SOICR) and cardiac arrhythmias [74]. This
emphasizes the importance of triadin in the struc-
tural and functional integrity of the cardiac Ca2+
release units. Physiological studies on skeletal muscle
revealed an important reduction in muscle strength,
and ultrastructural investigations uncovered abnor-
mally oriented T-tubules, strongly suggesting that
ECC is impaired [75].
Calsequestrin is the major Ca2+ storage protein
in the sarcoplasmic reticulum. It binds Ca2+ with
moderate affinity (Kd ∼ 103 M–1) and high capacity
(40–50 ions/protein), and forms higher-order poly-
mers with increasing Ca2+-binding capacities [76].
Calsequestrin also actively participates in the Ca2+
release process by providing a large Ca2+ pool in
close proximity to the RyR release channel [77]. Het-
erozygous CASQ1 missense mutations were found
in vacuolar myopathy (OMIM #616231) [78] and in
tubular aggregate myopathy (TAM) [79, 80], both
involving mild muscle weakness, but differing at the
histopathological level. Vacuolar myopathy biopsies
show vacuoles containing diverse SR proteins and
enlargement of the terminal SR cisternae [78], while
TAM muscle fibers typically accumulate densely
packed membrane tubules [81]. Both disorders arise
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from adverse mutational effects: the TAM-related
CASQ1 mutations were shown to significantly impair
calsequestrin polymerization, resulting in reduced
Ca2+ storage abilities of the SR, while the vacuo-
lar myopathy mutation promoted the formation of
high molecular mass polymers [78–80]. Notewor-
thy, Casq1 null mice exhibit a susceptibility to heat-
and anesthetics-induced sudden death resembling
malignant hyperthermia [82]. Recessive mutations in
the cardiac paralogue CASQ2 have been associated
with catecholamine-induced polymorphic ventricu-
lar tachycardia (CPVT, OMIM #114251) [83]. Whilst
dominant RYR2 mutations are found in about half of
the CPVT patients, recessive mutations inCASQ2 and
TRDN are more seldom and account for less than 5%
of the cases. Patients with CASQ2 mutations exhibit
a childhood-onset relative resting bradychardia and a
mild prolongation of the QTc segment, with Holter
monitoring showing polymorphic ventricular tachy-
cardia during exercise [83, 84]. In line with the
functional impact of CASQ1 mutations, it was shown
that the CASQ2 missense mutations alter the poly-
merization dynamics of calsequestrin, resulting in
reduced Ca2+ binding capacities [85]. It has been
proposed that the reduced Ca2+ buffering leads to
a higher level of unbound Ca2+ in the SR with an
increased risk for SOICR [86]. Indeed, mouse mod-
els harboring human CASQ2 mutations displayed
stress-induced spontaneous Ca2+ release leading to
ventricular tachycardia [87].
STORE-OPERATED CA2+ ENTRY (SOCE)
DISORDERS
Upon stimulation of the ryanodine receptor, Ca2+
is released to the cytoplasm to trigger muscle con-
traction and to regulate various signaling pathways.
The Ca2+ stores are refilled through store-operated
Ca2+ entry (SOCE), an essential mechanism for pro-
longed tetanic stimulation that limits the effects of
fatigue. The key players of SOCE are the reticular
Ca2+ sensor STIM1 and the plasma membrane Ca2+
channel ORAI1. STIM1 contains an intraluminal
region with Ca2+-sensing EF-hands, and a cytoso-
lic part able to interact with ORAI1 [13, 88]. Ca2+
store depletion initiates STIM1 unfolding, oligomer-
ization, and accumulation of the oligomers at the
SR/plasma membrane junctions, where they bind and
activate ORAI1 and thereby induce Ca2+ entry [11,
12, 89–92]. Ca2+ reuptake to the SR is ensured by
the ATP-dependent SERCA pumps.
Mutations in STIM1
Heterozygous missense mutations in STIM1 were
found in patients with tubular aggregate myopathy
(TAM, OMIM #160565), a rare muscle disorder
involving weakness, cramps, and myalgia, which
is characterized by the presence of densely packed
membrane tubules on biopsies [93]. TAM clinically
and genetically overlaps with Stormorken syndrome
(STRMK, OMIM #185070), a multi-systemic disor-
der associating TAM with miosis, thrombocytopenia,
ichthyosis, asplenia, dyslexia, and short stature [94,
95]. Although TAM and STRMK form a clini-
cal continuum, the Ca2+-binding EF-hand domains
appear to be a mutation hotspot in TAM patients
[93, 96–100], while the full clinical picture of Stor-
morken sydrome essentially arises from a substitution
of a single amino acid in the cytosolic domain of
STIM1 [101–103]. Nevertheless, TAM and STRMK
mutations were both shown to induce constitutive
STIM1 oligomerization and ORAI1 activation with-
out SR Ca2+ depletion in the cellular model, and
accordingly, TAM and STRMK myoblasts featured
increased basal Ca2+ levels in the cytosol [93,
100–103]. The multi-systemic phenotype of Stor-
morken syndrome might result from a different
mutational impact on Ca2+-dependent inactivation
(CDI) of the ORAI1 Ca2+ channel. Electrophysiolog-
ical studies on transfected cells demonstrated that the
STRMK mutation especially suppresses CDI, sug-
gesting a prolonged Ca2+ influx compared to TAM
[103]. SOCE is not restricted to skeletal or cardiac
muscle, but instead regulates Ca2+ homeostasis in
various tissues, explaining the broad phenotypical
presentation of Stormorken syndrome. A recently
generated mouse models harboring the STRMK
mutation recapitulated the main clinical features of
the human disorder [104]. The mice were smaller
than the control littermates, and displayed muscle
weakness, thrombocytopenia, spleen dysplasia, skin
irritations, and abnormal Ca2+ homeostasis in the
myotubes.
Mutations in ORAI1
ORAI1 is a highly Ca2+-specific plasma mem-
brane channel composed of hexamers forming three
concentric rings around the central pore, and each
ORAI1 subunit contains 4 alpha-helical transmem-
brane domains [105, 106]. Channel opening is
mediated through the interaction of STIM1 with
the cytoplasmic N- and C-termini of the ORAI1
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subunits [107]. Similarly to STIM1, heterozygous
missense mutations in ORAI1 cause TAM with
additional signs of Stormorken syndrome (OMIM
#615883). All mutations affect highly conserved
amino acids in the transmembrane domains [103,
108–110]. Exogenous expression of mutant ORAI1
resulted in elevated basal Ca2+ levels and significant
Ca2+ influx in the absence of Ca2+ store depletion
[108–110], and similar results were also obtained in
patient myotubes [109, 110]. Mutations in the first
transmembrane domain were especially shown to
cause a long-lasting Ca2+ influx, correlating with a
more severe disease phenotype [108].
MEMBRANE REMODELING DISORDERS
Remodeling of membranes is essential for normal
muscle function [111]. The skeletal muscle triad and
the cardiac dyad are specialized membrane struc-
tures with precise geometry, and the mechanical
stress exerted by steady contractions require effi-
cient membrane repair mechanisms. Consequently,
defects in proteins acting in membrane trafficking
and remodeling result in muscle disorders. The triad
and dyad formation and maintenance are coordinated
by the concerted action of various proteins including
myotubularin, amphiphysin 2, dynamin 2, caveolin,
and dysferlin, and mutations in any of the respective
coding genes lead to structural T-tubule defects in
animal models and humans [112].
Mutations in MTM1
Myotubularin, encoded by MTM1, is a 3-
phosphatase dephosphorylating the phosphoinosi-
tides PtdIns3P and PtdIns(3,5)P2 [113], which confer
a local signature to the membrane and play a key role
in the recruitment of proteins, in endocytosis, and
in membrane trafficking [114, 115]. MTM1 muta-
tions cause X-linked myotubular (or centronuclear)
myopathy (XLMTM, OMIM #310400), a severe
and generalized neonatal muscle disorder predomi-
nantly affecting boys and involving atrophic muscle
fibers, type I fiber predominance, centralized nuclei,
and sometimes basophilic rings known as necklace
fibers on muscle biopsies [116, 117]. Women can
also be affected, especially in case of skewed X-
inactivation, but the clinical presentation is often
milder [118]. More than 280 different causative
XLMTM mutations have been reported, and most
are nonsense mutations, splice-site mutations, or
deletions, and result in a strong reduction of the
myotubularin protein level and the dysregulation of
the phosphoinositide metabolism [119, 120]. Mice,
dogs, or zebrafish devoid of myotubularin exhib-
ited a disorganization of the triad structure, reduced
levels of RyR1 and DHPR, and defects in excitation-
contraction coupling [121–123].
Mutations in BIN1
Amphiphysin 2, encoded by BIN1, is able to
sense and induce membrane curvature in endocy-
tosis and recycling. It interacts with dynamin 2,
and connects the actin and microtubule cytoskeleton
to the nuclear envelope LINC (linker of nucle-
oskeleton and cytoskeleton) complex [124–126].
The skeletal muscle-specific isoform of amphiphysin
2 contains a phosphoinositide-binding domain and
plays a role in T-tubule biogenesis [127]. BIN1
mutations cause either dominant (ADCNM) [128]
or recessive (ARCNM, OMIM #255200) [129] cen-
tronuclear myopathy, and both disorders presumably
involve a different pathomechanism. ARCNM occurs
as a severe childhood-onset disorder predominantly
affecting the proximal muscles, and the biopsies
display atrophy, type I fiber predominance, and
nuclear centralization and clustering [129, 130].
ADCNM is clinically milder, has been described with
adulthood-onset muscle weakness, and the biopsies
of affected individuals exhibit nuclear centraliza-
tion and clustering as well as ultrastructural triad
abnormalities [128]. Comparative functional stud-
ies have shown that both dominant and recessive
BIN1 mutations prevent membrane tubulation and
interfere with protein-protein interactions, and that
only the defects caused by the recessive mutations
can be rescued by wild type amphiphysin 2 [128].
This is in accordance with the observation that het-
erozygous carriers of recessive BIN1 mutations are
healthy.
Mutations in DNM2
Dynamin 2 is a mechanochemical enzyme
involved in membrane fission and acting as a key
player for vesicle formation and membrane traffick-
ing at the plasma membrane and the trans-Golgi
network [131, 132]. It binds PtdIns(4,5)P2, inter-
acts with amphiphysin 2, and is able to self-assemble
into rings [132–135]. Heterozygous missense muta-
tions restricted to hotspots in the MID (middle), PH
(phospholipid binding), and GED (GTPase effector)
domains have been found in patients with autoso-
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mal dominant centronuclear myopathy (ADCNM,
OMIM #160150) [136, 137]. The clinical presen-
tation thereby correlates with the position of the
mutation, and ranges from severe neonatal hypotonia
and respiratory insufficiency to adult-onset distal
muscle weakness and mild eye movement defects
[138]. Histological findings on muscle biopsies
include myofiber atrophy, central nuclei, type I
fiber predominance, as well as prominent fiber size
variability and radial arrangements of sarcoplasmic
strands [130, 138]. Biochemical studies indicated that
the DNM2 mutations increase dynamin 2 oligomer
stability and GTPase activity [139, 140], and in vivo
investigations suggested that dynamin 2 is nega-
tively regulated by myotubularin and amphiphysin
2 [141, 142]. Knock-in mice harbouring the most
common human mutation R465W manifested a mild
myopathy with a structural disorganization of the
muscle fibers, abnormal contractile properties, and
elevated basal Ca2+ concentrations in the cytosol
[143, 144]. AAV-mediated expression of the same
mutation resulted in abnormal T-tubule structures
and a swollen sarcoplasmic reticulum [145], and
expression of the severe S619L mutation in zebrafish
revealed defective excitation-contraction coupling
[146].
Mutations in CAV3
Caveolin-3 is the principal protein component
of caveolae in muscle. Caveolae are cholesterol
and sphingolipid-rich invaginations of the plasma
membrane playing an important role in signal trans-
duction and vesicular transport [147]. Caveolin-3
belongs to the dystrophin-glycoprotein complex con-
ferring stability to the sarcolemma [148], and also
localizes to the developing T-tubules during mus-
cle differentiation [149]. Mutations in CAV3 give
rise to various skeletal and cardiac muscle disor-
ders including rippling muscle disease 2 (RMD2,
also known as limb-girdle muscular dystrophy 1C,
OMIM #606072) [150, 151], Tateyama distal myopa-
thy (OMIM #614321) [152], long QT syndrome 9
(LQT9, OMIM #611818) [153], and familial hyper-
trophic cardiomyopathy (CMH, OMIM #192600)
[154]. RMD2 is a childhood-onset muscle disorder
characterized by mild to moderate proximal muscle
weakness, cramps, myalgia, visible ripples moving
over the muscle following mechanical stimulation,
and elevated CK levels, and muscle biopsies from
affected individuals display dystrophic changes and
almost complete loss of caveolin-3 expression [150,
151, 155]. Tateyama distal myopathy mainly affects
the small muscles of the hands and feet, and the very
same CAV3 mutation can cause RMD2 or Tateyama
myopathy, suggesting that both disorders are part of
a clinical continuum. Long QT syndrome 9 is charac-
terized by a prolonged QT interval and polymorphic
ventricular arrhythmias potentially causing syncope,
seizure, or sudden death, and the causative CAV3
mutations were shown to induce an increased late
sodium current [153]. Hereditary ventricular hyper-
trophy is an idiopathic cardiomyopathy that manifests
with diastolic dysfunction of the cardiac ventricles,
and can entail arrhythmia, congestive heart failure,
and sudden death. As for the skeletal muscle disor-
ders, the CMH-related CAV3 mutation resulted in a
strongly reduced cell surface expression of caveolin-3
[154]. Mice lacking caveolin-3 showed a RMD2-
like mild myopathy, and investigations of the skeletal
muscle revealed disorganized T-tubule [156], high-
lighting the importance of caveolin-3 in T-tubule
biogenesis.
Mutations in DYSF
Dysferlin plays a crucial role in the process of
membrane repair, and co-localizes with caveolin-3 at
the site of the injury [157, 158]. It is also found in the
cytoplasm, and localizes with DHPR in the develop-
ing T-tubule system [159]. Mutations in DYSF have
been associated with Miyoshi muscular dystrophy
(MMD, OMIM #254130) [160], limb-girdle muscu-
lar dystrophy 2B (LGMDR2, formerly LGMD2D,
OMIM #253601) [160], and distal myopathy with
anterior tibial onset (OMIM #606768) [160]. Miyoshi
muscular dystrophy is an early-adult-onset disorder
involving distal muscle weakness of the upper and
lower limbs with sparing of the intrinsic hand mus-
cles [161]. Serum creatine kinase levels are increased,
and biopsies show a dystrophic pattern with necro-
sis. LGMDR2 patients generally present with a less
distal muscle involvement, and distal myopathy with
anterior tibial onset has been described in a single
consanguineous family with a rapidly progressive
course [160]. However, Miyoshi, LGMDR2, and
distal myopathy biopsies are similar, and all three
disorders can arise from identical DYSF mutations
resulting in strong reduction of dysferlin [160]. They
are therefore often conjointly referred to as dys-
ferlinopathies. Dysferlin-deficient mice developed a
progressive muscular dystrophy closely resembling
the human disease, and histological and ultrastruc-
tural analyses of muscle samples revealed T-tubule
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anomalies similar to what has been seen in Cav3 null
mice [157].
LINK BETWEEN CRC, SOCE AND
MEMBRANE REMODELING
CRC, SOCE and membrane remodeling are mech-
anistically interconnected, as CRC and SOCE concur
and require the formation and maintenance of special-
ized membrane structures. This explains why defects
in these key pathways cause similar disease entities.
It was proposed that amphiphysin 2 is essential for
the microtubule-dependent transport of DHPR to the
T-tubules in heart [162], and accordingly,Bin1knock-
down in murine cardiomyocytes resulted in decreased
surface DHPR, leading to impaired Ca2+ transients
[163]. Mtm1-deficient mice displayed a reduction in
protein levels and an abnormal localization of RyR1
and the 1 subunit of DHPR, most probably con-
tributing to the altered triad structure and the defective
Ca2+ transients observed in the animals [121, 164].
DHPR also interacts with dysferlin and caveolin-
3, and it has been suggested that the formation of
this oligomeric complex plays a role in the fusion
of caveolin-3-containing vesicles with T-tubules
[159].
Phosphoinositides are critical for triad and dyad
structure, excitation-contraction coupling, as well as
SOCE. The membrane repair capacities of dysfer-
lin largely depend on its Ca2+-dependent binding of
PtdIns4P and PtdIns(4,5)P2 [165], and the latter is
also crucial for the recruitment of amphiphysin 2 and
dynamin 2 to the membrane [133, 166]. PtdIns(3,5)P2
modulates skeletal muscle and heart contractibility
through activation of RyR1 and RyR2 [167–169],
and increased levels of PtdIns(3,5)P2 were shown to
induce chronic Ca2+ leakage from the sarcoplasmic
reticulum, and promoted the degradation of DHPR
[167, 168, 170]. Other studies highlighted the impor-
tance of phosphoinositides in SOCE: STIM1 interacts
with PtdIns(4,5)P2 through its polybasic C-terminus,
and inhibition of phosphatidylinositol 4-kinase pre-
vents the formation of STIM1 oligomers at the plasma
membrane [171]. The inhibition of phosphatidylinos-
itol 4-kinases but not isolated PtdIns(4,5)P2 depletion
also significantly reduced store-operated Ca2+ entry,
indicating that PtdIns4P is a determinant for SOCE
activation [172]. STIM1 was also found to bind the
1 subunit of DHPR in cardiac cells and to suppress
the depolarization-induced channel opening [173]. In
turn, STIM1 is negatively regulated by low polymeric
forms of calsequestrin, which interfere with STIM1-
ORAI1 interactions [174], demonstrating a reciprocal
regulation of CRC and SOCE and the importance of
the membrane structures these pathways rely on.
CONCLUSIONS
Cardiac and skeletal muscle contraction rely on
similar membrane structures and the coordinated
action of identical or evolutionary related proteins.
Although a variety of cardiac and skeletal muscle
disorders arise from structural or functional dyad
or triad defects, only mutations affecting the Ca2+
release complex were found in malignant hyper-
thermia and in both cardiopathies and congenital
myopathies. Mutations in CACNA1C, RYR2, and
CASQ2 cause life-threatening arrhythmias primarily
resulting from spontaneous SR Ca2+ release follow-
ing exercise, and mutations in the skeletal muscle
paralogues CACNA1S, RYR1, and CASQ1 cause mus-
cle weakness resulting from reduced Ca2+ release
upon ECC activation. With CAV3 as the only excep-
tion, mutations in genes implicated in membrane
remodeling or SOCE were found in patients with
congenital myopathies, but weren’t associated with
hyperthermia or heart diseases. Noteworthy, muta-
tions in the SOCE genes STIM1 and ORAI1, as well as
in the membrane remodeling genes BIN1 and DNM2
mostly involve amino acid substitutions, and do not
result in total protein loss [93, 109, 129, 137]. Knock-
out animal models for these genes exist, and some
of them displayed cardiac defects. Cardiomyocyte-
restricted knockout of Stim1 in mice resulted in
a progressive decline of left ventricular function
and the development of a dilated cardiomyopathy
[175], and inactivation of the zebrafish orthologue
of ORAI1 entailed reduced ventricular systolic func-
tion, bradycardia, and heart failure [176]. A critical
role of STIM1 and ORAI1 has also been suggested
in the pathogenesis of cardiac hypertrophy in humans
[177]. Mice with heart-specific Bin1 deletion exhib-
ited decreased T-tubule folding at the dyad and
were susceptible to ventricular arrhythmias result-
ing from prolonged action potential duration [178].
In zebrafish hearts, bin1 knockdown significantly
reduced Ca2+ transients and led to severe ventricular
contractile dysfunction [163], and in humans, BIN1
expression was shown to be significantly decreased
in failing cardiomyocytes [163]. Lastly, mice with
dysferlin deficiency developed a mild cardiomyopa-
thy that was exacerbated by stress exercise [179].
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These examples demonstrate that SOCE and mem-
brane remodeling are critical for normal skeletal and
cardiac muscle function, and that mutations in the
genes encoding key proteins of these pathways might
account for molecularly yet uncharacterized heart
diseases.
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